|Mr. Gregory P. Madison||CEO & Exec. Director||432.57k||N/A||1968|
|Dr. Christian Schweiger M.D., Ph.D.||Co-Founder & Non Exec. Director||50k||N/A||1967|
|Mr. Hans-Peter Rudolf||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Lucy Huntington-Bailey||Gen. Counsel & Company Sec.||N/A||N/A||N/A|
|Ms. Suzanne Wood||Group HR Director||N/A||N/A||N/A|
|Ms. Carol Akinola||Head of Pharmacovigilance & Medical Information||N/A||N/A||N/A|
|Dr. José A. Menoyo M.D.||Chief Medical Officer||N/A||N/A||N/A|
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.